{"url_path":"/sec/cphi/8-k/2026-07-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1106644/0001213900-26-080475-index.html","accession_number":"0001213900-26-080475","cik":"0001106644","ticker":"CPHI","issuer_name":"CHINA PHARMA HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1106644/0001213900-26-080475-index.html","primary_entity_key":"0001106644","primary_entity_name":"CHINA PHARMA HOLDINGS, INC."},"word_count":117,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits**\n\n** **\n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Exhibit Title or Description**\n\n5.1\n \n[Opinion of Flangas Law Group](ea029892101ex5-1.htm)\n\n10.1\n \n[Form of Securities Purchase Agreement](ea029892101ex10-1.htm)\n\n10.2\n \n[Form of Placement Agency Agreement](ea029892101ex10-2.htm)\n\n23.1\n \n[Consent of Flangas Law Group (included in Exhibit 5.1)](ea029892101ex5-1.htm)\n\n99.1\n \n[Press Release dated as of July 22, 2026](ea029892101ex99-1.htm)\n\n104\n \n\nCover Page Interactive Data File\n(embedded within the Inline XBRL document).\n\n \n\n1\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nDated: July 22, 2026\n\n \n\n \n**CHINA PHARMA HOLDINGS, INC.**\n\n \n \n\n \nBy:\n/s/ Zhilin Li\n\n \n \nName: \nZhilin Li\n\n \n \nTitle:\nPresident and Chief Executive Officer\n\n \n\n2"}